Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gigacloud Technology Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Gigacloud Technology Inc trades at $34.35 (market cap $1.25B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 31.9× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GCT | |
|---|---|---|
Market Cap | $39.89B | $1.25B |
Sector | Health | Technology |
52-Week High | $491.22 | $51.80 |
52-Week Low | $278.09 | $20.26 |
Enterprise Value | $38.15B | $1.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GigaCloud Technology (GCT) trades at $34.41, down 1.21% today, with a bullish technical signal and strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate, and maintains robust profitability with a 10.77% net income margin. Revenue growth is projected to rise from $1.29B in 2025 to $1.4B in 2026, supported by positive analyst sentiment and inclusion in TIME's World's Growth Leaders 2026 list.
The outlook for GCT is positive, driven by earnings momentum and strategic expansions into Europe and AI-edge technology. Key risks include market volatility, competitive pressures in the furniture sector, and potential fiduciary concerns highlighted in recent news. With 66.7% of analysts rating it a Buy and a $56 price target from Seeking Alpha suggesting 76% upside, the stock presents growth potential but requires monitoring of execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
